PODD vs TNDM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PODD is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PODD and TNDM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PODD and TNDM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Insulet Corporation sells one thing extremely well. The Omnipod is a small adhesive pod worn on the body that holds insulin and delivers it without tubing, controlled by a phone app or a handheld. The current generation, Omnipod 5, is an automated insulin delivery system: it reads a continuous glucose monitor (Dexcom G7 or Abbott's FreeStyle Libre) and adjusts basal insulin automatically. The pods are disposable and replaced every three days, so the business is a classic razor-and-blade model where each new user converts into a predictable multi-year consumable stream. Insulet also distributes most of its US volume through the pharmacy channel rather than durable medical equipment, which lowers the friction of getting a patient started and has been a structural advantage over tubed competitors. A small drug delivery segment supplies pod technology to a pharmaceutical partner, but it is under ~2% of revenue and shrinking by design.

Full PODD guide

Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.

Full TNDM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• PODD drivers: Installed base compounding through pods; International expansion.
• TNDM drivers: Recurring supplies and a growing installed base; Tandem Mobi and Control-IQ+ product cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Type 2 retention is the live risk and the reason the shares derated: if attrition inside the first 90 days does not improve, the largest piece of the long-term growth story shrinks, and management's preliminary 2027 view of only mid-teens constant-currency growth already assumes no benefit from the fixes. For TNDM, competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick PODD if you believe its drivers more; TNDM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PODD and TNDM guides.

PODD. Insulet guided full-year 2026 revenue to roughly $3.2-3.3 billion with constant-currency growth of ~20-22%, trimmed from ~21-23%, and cut US Omnipod growth to ~17-19% while raising international to ~30-32%. The cut was small in dollars but changed the narrative: the shares fell about 20% on August 5, 2026 and, at about $142 in mid-October, remain down about 13% over three months and 55% over a year against a 52-week high of ~$355. At roughly 18x forward earnings the stock prices in materially slower growth than it did a year earlier; consensus for Q3, due November 4, is about $1.59 of EPS on ~$833 million of revenue.

TNDM. Tandem is best read as a growth medtech rather than a mature, profitable company, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio. At about 1.1 times trailing sales and roughly $1.2 billion in market value, the shares price in modest expectations for a business that analysts see moving to small profits in 2027; the forward P/E near 107 mostly reflects how thin those projected earnings still are. Third-quarter results on November 5, 2026 come with a consensus of about $265.9 million in revenue and a loss of $0.24 per share.

Headline figures (approximate, October 2026): PODD shows revenue (ttm) ~$3.05B, q2 2026 revenue ~$802M, up ~23.5% year over year, adjusted gross margin (q2 2026) ~72.9% (GAAP gross margin TTM ~71%), net income / eps (ttm, gaap) ~$375M / ~$5.34; TNDM shows revenue (ttm) ~$1.04 billion, revenue growth (latest quarter) ~6% year over year (Q2 2026: ~$254.6M), gross margin (ttm) ~56%; operating margin ~-5%, net income (ttm) ~-$63 million; EPS ~-$0.91.

PODD and TNDM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined PODD and TNDM exposure against your real portfolio. It is not an investment adviser.